Recital 6, Regulation (EU) 2020/2007

In forcesince 8 Dec 2020

In order to ensure a balanced distribution of responsibilities and work among Member States acting as rapporteurs and co-rapporteurs and taking into account the resources necessary for assessment and decision-making, it is appropriate to extend the approval periods of certain active substances as set out in Implementing Decision C/2018/3434. The approval periods of 1,4-dimethylnaphthalene, Adoxophyes orana granulovirus, Aureobasidium pullulans (strains DSM 14940 and DSM 14941), Bacillus pumilus QST 2808, benalaxyl-M, Pseudomonas sp. strain DSMZ 13134, pyridalyl, pyriofenone, pyroxsulam and Streptomyces lydicus strain WYEC 108 should be extended by one year. For the same reasons, it is appropriate to extend the approval periods of the active substances bixafen, Candida oleophila strain O, disodium phosphonate, fluxapyroxad, Paecilomyces fumosoroseus strain FE 9901, penflufen, penthiopyrad, potassium phosphonates and sedaxane by one to three years, respectively.

  • celex=32018D3434